Pioglitazone is a valid alternative to rosiglitazone

American Journal of Cardiovascular Drugs

Volumn 11, Issue 6, 2011, Pages 357-362

  Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

pioglitazone; rosiglitazone; type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ANGINA PECTORIS; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; DIABETIC KETOACIDOSIS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FRACTURE; GLYCEMIC CONTROL; GROUPS BY AGE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; LIVER TOXICITY; MEDICAL HISTORY; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; SIDE EFFECT; STROKE; TREATMENT RESPONSE;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; HYPOGLYCEMIC AGENTS; SAFETY-BASED DRUG WITHDRAWALS; THIAZOLIDINEDIONES;

EID: 83055198551     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11595990-000000000-00000     Document Type: Review

References (58)

1. Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 2009; 5: 141-51
2. Derosa G, Salvadeo SAT, D'Angelo A, et al. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Arch Med Res 2008; 39: 412-9
3. Derosa G, Maffioli P, Salvadeo SAT, et al. Direct comparison among oral ypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: The 60's study. Metabolism 2009; 58: 1059-66
4. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-409 (Pubitemid 32056079)
5. Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 453-60
6. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study. Clinl Therap 2005; 27: 1548-61 (Pubitemid 41739491)
7. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: The EMPIRE Study. Curr Med Res Opin 2005; 21: 2029-35 (Pubitemid 41803114)
8. Home PD, Bailey CJ, Donaldson J, et al. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabet Med 2007; 24: 618-25 (Pubitemid 46808868)
9. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009; 11 (12): 1091-9
10. Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther 2010; 12 (6): 491-501
11. Ceriello A, Johns D, WidelM, et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28 (2): 266-72 (Pubitemid 40170924)
12. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-104 (Pubitemid 40909644)
13. Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy withaddition of pioglitazone to metformin compared with the addition of gliclazide tometformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes Metab Res Rev 2005; 21: 167-74 (Pubitemid 40467663)
14. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007; 30 (5): 387-94 (Pubitemid 46958888)
15. DerosaG,D'angeloA,Ragonesi PD, et al.Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res 2006; 34 (5): 545-55 (Pubitemid 44756143)
16. Derosa G, Cicero AF, D'angelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28 (11): 917-24 (Pubitemid 43173962)
17. Bolen S, Wilson L, Vassy J, et al. Systematic review: Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Ann Intern Med 2007; 147 (6): 386-99 (Pubitemid 351664540)
18. Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis. Diabetes Care 2010; 33 (8): 1859-64
19. Derosa G, D'Angelo A, Salvadeo SA, et al. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother 2009; 63 (10): 723-33
20. Derosa G, Mereu R, D'Angelo A, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther 2010; 35: 565-79
21. Rizza S, Cardellini M, Porzio O, et al. Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 2011; 215 (1): 180-3
22. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17 (1): 40-7 (Pubitemid 30094179)
23. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and osiglitazione combination therapy in patients with type 2 diabetes mellitus: A randomised controlled trial. JAMA 2000; 283 (13): 1695-702 (Pubitemid 30196209)
24. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Am J Med 2001; 111 (1): 10-7 (Pubitemid 32635256)
25. Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-83 (Pubitemid 44060202)
26. Derosa G, D'Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 2007; 37 (2): 79-86 (Pubitemid 46066616)
27. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-54 (Pubitemid 38736964)
28. Goldberg RB, Kendall DM, Deeg MA, et al., the GLAI Study Investigators. Acomparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.Diabetes Care 2005; 28: 1547-54 (Pubitemid 40923063)
29. Deeg MA, Buse JB, Goldberg RB, et al., GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30: 2458-64 (Pubitemid 47547772)
30. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-96 (Pubitemid 34275860)
31. Kintscher U. Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference? J Am Coll Cardiol 2008; 52: 882-4
32. Derosa G, D'Angelo A, Salvadeo SA, et al. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism 2008; 57 (11): 1552-7
33. Derosa G, Mereu R, Salvadeo SAT, et al. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Intern Med 2009; 48: 265-71
34. Derosa G, Maffioli P, Salvadeo SAT, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010; 59: 887-95
35. Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010; 42: 663-9
36. Bloomgarden ZT. The Avandia debate. Diabetes Care 2007; 30: 2401-8 (Pubitemid 47359054)
37. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006; 368: 1096-105
38. Nissen SE. The DREAM trial [letter]. Lancet 2006; 368 (9552): 2049
39. Kahn SE, Haffner SM, Heiase MA, and the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43 (Pubitemid 44903747)
40. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356 (24): 2457-71 (Pubitemid 46919772)
41. Information for Healthcare Professionals. Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl); 21 May 2007 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfor mationforPatientsandProviders/ucm143460.htm [Accessed 2011 Aug 1]
42. Home PD, Pocock SJ, Beck-Nielsen H, RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-35
43. Kaul S,Diamond GA. Rosiglitazone and cardiovascular risk. CurrAtheroscler Rep 2008; 10 (5): 398-404
44. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304 (4): 411-8
45. Nissen SE, Wolski K. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. N Arch Intern Med 2010; 170 (14): 1191-201
46. Law BM. Avandia meta-analysis sparks confusion, questions.DOCNews 2007 [online]. Available from URL: http://docnews.diabetesjournals.org/content/ 4/7 [Accessed 2010 Nov 28]
47. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25 (4): 708-11 (Pubitemid 41071191)
48. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7: 162-9 (Pubitemid 32514871)
49. Gegick CG, Altheimer MD. Thiazolidinediones: Comparison of long-term effects on glycemic control and cardiovascular risk factors. Curr Med Res Opin 2004; 20: 919-30 (Pubitemid 38821531)
50. Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive investigators. Secondary prevention ofmacrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro- Vascular Events): A randomised controlled trial. Lancet 2005; 366 (9493): 1279-89 (Pubitemid 41416583)
51. Sparkman J, Stroup J, Schupbach R, et al. Metabolic effects of a conversion from rosiglitazone to pioglitazone in Native American patients with type 2 diabetes. Proc (Bayl Univ Med Cent) 2007; 20: 349-53
52. Derosa G, Cicero AF, D'Angelo A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006; 28 (5): 679-88 (Pubitemid 44067262)
53. Triay J, Raghavan R, Day A, et al. Benefit of switching from rosiglitazone to pioglitazone on cardiovascular markers in routine clinical practice [abstract no. P275]. Presented at the European Congress of Endocrinology; 2010 April 24-28; Prague, Czech Republic 24-28
54. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents. Drugs 2010; 70 (15): 1945-61
55. National Health System. CG66: Type 2 diabetes: full guideline [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action=down load&o=40803 [Accessed 2010 Nov 29]
56. Phatak HM, Yin DD. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): A meta-analysis of published randomized clinical trials. Curr Med Res Opin 2006; 22: 2267-78 (Pubitemid 44801495)
57. Takeda. Actos: summary of product characteristics. 2009 [online]. Available from URL: http://emc.medicines.org.uk/medicine/4236 [Accessed 2010 Nov 29]
58. Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): Risk of fracture. CMAJ 2007; 177 (7): 723-4